Commentary · 20 Jun 2023
Conference abstractPublished 29 Sep 2014
Autoimmune hepatitis: Evolution/development and treatment
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
HCV infection is associated with several autoimmune co-morbidities such as cryoglobulinaemia, or even malignant pathologies, for example lymphomas. Many HCV patients have circulating autoantibodies. For example, 70% of patients with hepatitis C have circulating rheumatoid factor. Approximately one third have cryoglobulins, and anywhere from 13% to 21% have low-titer or high-titer antinuclear antibodies (ANA). A slightly lower percentage have smooth muscle antibodies? about 5% have antibodies to liver or kidney microsomes?and about 7% have antithyroid antibodies. A direct relationship between systemic lupus (SLE) and HCV infection has been described. There may be a possible causal link between HCV and SLE: there is a high prevalence of HCV infection in SLE patients and a higher prevalence of liver involvement in HCV- positive patients with SLE. Constant immune proliferation and clonal expansion of B cells driven by hepatitis C can at times transfer or progress to B-cell lymphoma. In HCV patients, B cell non-Hodgkin lymphoma may evolve either related to mixed cryoglobulinaemia type II or in patients without cryoglobulinaemia. This talk aims to draw the attention towards the importance of correct and complete evaluation of HCV patients in respect to such co-morbidities. The author will discuss three cases of HCV infection associated with different pathologies (cryoglobulinaemia, SLE, B cell lymphoma), study their diagnosis, evolution and prognosis from the clinical and paraclinical point of views and review the literature data.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 14 Apr 2025
Developing novel antigen specific therapies as autoimmune disease treatments
Perspective · 13 Mar 2023
Developments in Autoimmunity Research: Advances in Treatment and Prevention
Conference abstract · 26 Nov 2018
Development of IMU-838, an orally available and selective small molecule inhibitor for the treatment of chronic inflammatory and autoimmune diseases
Conference abstract · 3 Oct 2016
Targeting the phospholipase A2 – Autotaxin Axis: A challenge to develop novel agents for the treatment of inflammatory and autoimmune diseases
More from this journal
The newest in Journal of Clinical and Cellular Immunology.
Perspective · 10 Sep 2026
Cellular Pathways Involved in Mucosal Immunity and Protection Against Environmental Challenges
Commentary · 22 Jul 2026
From Bench to Bedside: Reframing the CXCL13/CXCR5 Axis as a Non-Redundant Organizer of Protective Pulmonary Immunity in COVID-19
Commentary · 17 Jul 2026
CD5L:p40, a third wheel to IL-12 and IL-23 biology?
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical and Cellular Immunology
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Laura Iliescu”

